Caribou reports positive vispa-cel phase 1 data: 82% ORR, 64% CR in 2L LBCL; cash ~$159.2M

Caribou Biosciences, Inc.

Vispa-cel confirmatory cohort (N=22): 82% ORR, 64% CR rate, 51% 12-month PFS in 2L LBCL.
Optimized profile cohort (N=35): 86% ORR, 63% CR rate, 53% 12-month PFS; median follow-up 11.8 months.
CB-011 (BCMA) dose escalation: 92% ORR, 75% CR/sCR at RDE (450M cells) in BCMA-naïve r/r MM; dose expansion by end 2025.
Planned pivotal phase 3 for vispa-cel in 2L LBCL: FDA recommends randomized controlled trial, ~250 patients, PFS primary endpoint.
Preliminary cash, equivalents, and marketable securities as of Sep 30, 2025: approximately $159.2 million.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.